<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75605</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hypercoagulable workup in ophthalmology. When and What?</dc:title>
<dc:description xml:lang="en">ABSTRACTMost ophthalmologic disorders secondary to hypercoagulabestate are due to the confluence of congenitaland adquired factors. A systematic workup ismandatory.Most of congentital coagulation disorders causevenous trombosis and are inherited autosomaldominantly. In order of frequency these are factor VLeiden mutation (activated protein C resistance),G20210A mutation of the prothrombin gen and proteinC, protein S, and antithrombin III deficiencies.Sickle cell anemia can determine arerial and venousthrombosis.In relation with arterial occlusion, the markers mostfrequently involved are homcysteine fasting levelsand the markers of antiphospholipid antibodysyndrome. Both of them can also determine venousthrombosis.Several acquired factors can lead to hypoercoagulablestate, especially hyperhomocysteinemia, antiphospholipidantibody syndrome, hepatic disease,alcohol and tobacco intake, oral contraceptives,immobilization, surgeries and malignancies.In central venous occlusion is only necessary to ruleout hyperhomocysteinemia and antiphospholipidantibody syndrome in young patients without known risk factors.                   In central artery occlusion, hypercoagulable workupis only recommended for patients less than 50years-old with unknown emboli source. In thiscases protein C, protein S, and antithrombin IIIdeficiencies, homocystein, sickle cell diseae andantiphospholipid antibody syndrome will ruled out.In non arteritic ischemic optic neuropathy hypercoagulablework up is not necessary.In amaurosis fugax without known emboli source, it is recommended to rule out etiologies of arterial occlusion, especially antithrombin III deficiencies, homocystein, sickle cell diseae and antiphospholipid antibody syndrome(AU)             </dc:description>
<dc:creator>Muñoz-Negrete, F. J</dc:creator>
<dc:creator>Rebolleda, G</dc:creator>
<dc:creator>Casas-Lleras, P</dc:creator>
<dc:creator>Pérez-López, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Ante una amaurosis fugax sin fuente embolígenaconocida se recomienda la búsqueda de alteracionesrelacionadas con oclusiones arteriales, fundamentalmentedéficit de antitrombina III, hiperhomocisteinemia,síndrome antifosfolípido y la enfermedadde células falciformes(AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;84(7): 325-332, jul. 2009. tab</dc:source>
<dc:identifier>ibc-75605</dc:identifier>
<dc:title xml:lang="es">Estudios de hipercoagulabilidad en oftalmología. ¿Qué pedir y cuándo?</dc:title>
<dc:subject>^d33361^s22080</dc:subject>
<dc:subject>^d2581</dc:subject>
<dc:subject>^d33361^s22027</dc:subject>
<dc:subject>^d19336</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d19336^s22067</dc:subject>
<dc:subject>^d33361^s22053</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d33361</dc:subject>
<dc:subject>^d10065</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d33361^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200907</dc:date>
</metadata>
</record>
</ibecs-document>
